Abiomed to present new data from PROTECT II research in PCI in SCAI meeting Abiomed Inc.

The presentation, ‘A Prospective Multicenter Randomized Clinical Trial of Intra-aortic Balloon Pump vs Impella for Hemodynamic Support During RISKY PCI: 90 Day Results from PROTECT II’ will end up being one of four late-breaking clinical trial presentations to become showcased at the meeting. For Fri The PROTECT II display is scheduled, May 6 at 12 p.m. ET at the Hilton Baltimore. Related StoriesInnovation in anaesthesia: an interview with Matti Lehtonen, GE HealthcareAngiography and MPI: an interview with Professor Mauro Magnani University of UrbinoFidgeting while sitting down may be good for usPROTECT II was a potential multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high risk percutaneous coronary intervention .All medical and pharmacy state costs were added up to look for the total cost of care. A total of 15,043 people were followed for just one year. Of that combined group, 73.9 % were adherent to their medication and 26.1 % were non-adherent. While those individuals adherent to DM medicine experienced higher pharmacy costs which resulted in an boost in the overall total cost of care , those sticking with medicines were found to get a 31 % lower threat of hospitalization and significantly lower general medical costs than the non-adherent group.

Nicholas H. Gaffga, M.D., M.P.H., Casey Barton Behravesh, D.V.M., Dr.P.H., Paul J. Ettestad, D.V.M., Chad B. Smelser, M.D., Andrew R. Rhorer, M.S., Alicia B. Cronquist, R.N., M.P.H., Nicole A.